SMART Therapy with Symbicort
The SMART (Single Maintenance And Reliever Therapy) regimen uses budesonide/formoterol (Symbicort) as both a daily maintenance medication AND as-needed reliever therapy in a single inhaler, and is strongly recommended by the 2020 NAEPP guidelines for patients aged 4 years and older with moderate to severe persistent asthma. 1
What SMART Therapy Is
SMART is a simplified asthma management strategy where patients use the same budesonide/formoterol inhaler for:
- Maintenance dosing: Typically 2 inhalations twice daily
- Reliever dosing: Additional inhalations as needed for symptom relief (instead of using a separate SABA inhaler)
This approach replaces the traditional regimen of fixed-dose ICS/LABA maintenance plus separate short-acting beta-agonist (SABA) reliever.
Guideline Recommendations
The 2020 NAEPP Expert Panel provides strong recommendations with high certainty of evidence for SMART therapy 1:
For ages 4+ with moderate to severe persistent asthma: ICS-formoterol as both daily controller and reliever therapy is strongly recommended over:
- Higher-dose ICS as daily controller with SABA for quick relief
- Same-dose ICS-LABA as daily controller with SABA for quick relief
For ages 12+ with moderate to severe persistent asthma: Conditional recommendation (high certainty evidence) for SMART over higher-dose ICS-LABA maintenance plus SABA reliever 1
Clinical Trial Evidence Supporting SMART
The landmark SMART trials demonstrated substantial benefits 2:
- 44% reduction in risk of first severe exacerbation (HR 0.56, p=0.033)
- 38% reduction in overall exacerbation rates (0.16 vs 0.26 events/patient-year, p=0.024)
- Fewer days of high β-agonist use without medical review (49% reduction, p=0.001)
- Reduced oral corticosteroid exposure despite higher inhaled corticosteroid use
- No significant difference in composite systemic corticosteroid burden
Pediatric data (ages 4-11) showed even more dramatic results 3:
- 70-79% reduction in exacerbations requiring medical intervention vs fixed-dose regimens
- Prolonged time to first exacerbation
- Improved growth by 1.0 cm/year vs higher fixed-dose ICS
Real-World Effectiveness
Multiple open-label studies comparing SMART to conventional best practice demonstrated 4, 5:
- 15% fewer exacerbations (0.20 vs 0.24/patient/year, p=0.021)
- 27% lower mean ICS dose (p<0.0001)
- Better odds of remaining well-controlled (OR 1.29, p<0.01)
- Lower drug costs (51.3 vs 66.5 euros/patient/month in Belgian study)
Key Clinical Considerations
Overuse monitoring: The SMART regimen has a favorable safety profile regarding β-agonist overuse 2:
- 56% of SMART patients had at least one high-use episode vs 45% with standard therapy (not statistically significant, p=0.058)
- However, SMART patients had fewer total days of high use (5.1 vs 8.9 days, p=0.01)
- Real-world Korean data showed only 17.1% of patients overused on at least one day 6
Populations at higher risk for overuse require closer monitoring 6:
- Younger patients
- Those with limited physical activity
- Patients with nocturnal symptoms
ICS exposure: SMART increases inhaled corticosteroid exposure by approximately 22% compared to fixed-dose regimens, but this is offset by reduced oral corticosteroid use and better exacerbation control 2.
GINA Guidelines Integration
GINA guidelines have incorporated SMART as a preferred option at Steps 3-5 for moderate to severe asthma 7. The approach provides:
- Greater or equal sustained asthma control vs higher fixed doses
- Simplified dosing that may improve adherence
- Fast symptom relief with anti-inflammatory effect
Critical caveat: SMART success depends on proper patient education about the dual role of the inhaler—both maintenance and reliever. Patients must understand they need regular twice-daily dosing PLUS additional inhalations for symptoms, not just as-needed use alone.